These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1060 related items for PubMed ID: 18515009

  • 21. [Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
    Xiu Bing-He, Consensus Expert Group For Prevention Diagnosis And Treatment Of Bone Loss And Osteoporosis In Postmenopausal Breast Cancer Patients After Aromatase Inhibitor Therapy.
    Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):876-9. PubMed ID: 24447490
    [No Abstract] [Full Text] [Related]

  • 22. Adverse bone effects during pharmacological breast cancer therapy.
    Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P.
    Acta Oncol; 2008 Nov; 47(4):747-54. PubMed ID: 18465344
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Effect of aromatase inhibitors on bone metabolism].
    Folkestad L, Bjerregaard JK, Bjarnason NH, Brixen KT.
    Ugeskr Laeger; 2007 May 07; 169(19):1774-9. PubMed ID: 17537350
    [Abstract] [Full Text] [Related]

  • 25. Osteoporosis risk in premenopausal women.
    Vondracek SF, Hansen LB, McDermott MT.
    Pharmacotherapy; 2009 Mar 07; 29(3):305-17. PubMed ID: 19249949
    [Abstract] [Full Text] [Related]

  • 26. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
    Aapro M.
    Breast; 2006 Feb 07; 15 Suppl 1():S30-40. PubMed ID: 16500238
    [Abstract] [Full Text] [Related]

  • 27. Management of bone loss induced by aromatase inhibitors.
    Gnant M.
    Cancer Invest; 2006 Feb 07; 24(3):328-30. PubMed ID: 16809162
    [Abstract] [Full Text] [Related]

  • 28. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K, Blinder VS, Elkin EB.
    J Clin Oncol; 2012 May 01; 30(13):1468-75. PubMed ID: 22370313
    [Abstract] [Full Text] [Related]

  • 29. Adjuvant aromatase inhibitors and bone health.
    Chowdhury S, Pickering LM, Ellis PA.
    J Br Menopause Soc; 2006 Sep 01; 12(3):97-103. PubMed ID: 16953982
    [Abstract] [Full Text] [Related]

  • 30. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
    Waltman NL, Ott CD, Twiss JJ, Gross GJ, Lindsey AM, Moore TE.
    Cancer Nurs; 2008 Sep 01; 31(3):182-90. PubMed ID: 18453874
    [Abstract] [Full Text] [Related]

  • 31. Osteoporosis: new hope for the future.
    Masi L, Bilezikian JP.
    Int J Fertil Womens Med; 1997 Sep 01; 42(4):245-54. PubMed ID: 9309458
    [Abstract] [Full Text] [Related]

  • 32. Effects of third-generation aromatase inhibitors on bone.
    McCloskey E.
    Eur J Cancer; 2006 May 01; 42(8):1044-51. PubMed ID: 16554149
    [Abstract] [Full Text] [Related]

  • 33. Practical guidance for the management of aromatase inhibitor-associated bone loss.
    Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M.
    Ann Oncol; 2008 Aug 01; 19(8):1407-1416. PubMed ID: 18448451
    [Abstract] [Full Text] [Related]

  • 34. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S.
    J Clin Oncol; 2008 Oct 20; 26(30):4875-82. PubMed ID: 18725648
    [Abstract] [Full Text] [Related]

  • 35. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2006 Oct 20; 13(3):340-67; quiz 368-9. PubMed ID: 16735931
    [Abstract] [Full Text] [Related]

  • 36. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
    Clunie GP, Clark A, Mortimer CJ, Stephenson S, Aitken J, Smith C, Sherwin E, Archer TJ.
    Eur J Surg Oncol; 2009 May 20; 35(5):475-80. PubMed ID: 18950981
    [Abstract] [Full Text] [Related]

  • 37. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
    Swenson KK, Nissen MJ, Anderson E, Shapiro A, Schousboe J, Leach J.
    J Support Oncol; 2009 May 20; 7(3):101-7. PubMed ID: 19507458
    [Abstract] [Full Text] [Related]

  • 38. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA.
    Clin Breast Cancer; 2009 Feb 20; 9(1):34-8. PubMed ID: 19299238
    [Abstract] [Full Text] [Related]

  • 39. The effect of aromatase inhibitors on bone metabolism.
    Folkestad L, Bjarnason NH, Bjerregaard JK, Brixen K.
    Basic Clin Pharmacol Toxicol; 2009 Jan 20; 104(1):3-10. PubMed ID: 19152547
    [Abstract] [Full Text] [Related]

  • 40. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ.
    Breast; 2007 Jun 20; 16(3):223-34. PubMed ID: 17368903
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.